摘要 |
Disclosed is the use of a humanized anti-CD4 antibody capable of activating CD4+CD25+ regulatory T cells for the manufacture of a pharmaceutical composition for treating an autoimmune disease in a subject, wherein the humanized anti-CD4 antibody comprises an H chain V domain, an L chain V domain and an IgG 1 constant domain wherein: (a) the H chain V domain comprises the sequences DCRMY, VISVKSENYGANYAESVRG and SYYRYDVGAWFAY, and the L chain V domain comprises the sequences RASKSVSTSGYSYIY, LASILES and QHSRELPWT; and/or (b) the H chain V domain has at least 90% sequence identity with SEQ ID No: 1 and the L chain V domain has at least 90% sequence identity with SEQ ID No: 2, wherein the composition is to be administered to the subject from every week to every 31 days, and wherein the composition is to be administered to the subject in a dose of the humanized anti-CD4 antibody of: (i) from 10 to 200 mg; (ii) from 6 to 60 mg/m2 body surface area of the subject; or (iii) from 0.2 to 1.5 mg/kg. |